TRCT
DMRA

Tower Research Capital (TRC)’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Tower Research Capital (TRC)’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.7K Buy
1,418
+1,242
+706% +$31.9K ﹤0.01% 3007
2025
Q4 		$4.05K Sell
176
-1,251
-88% -$21.7K ﹤0.01% 4267
2025
Q3 		$5.31K Buy
1,427
+485
+51% +$1.64K ﹤0.01% 4247
2025
Q2 		$3.21K Sell
942
-641
-40% -$1.9K ﹤0.01% 4534
2025
Q1 		$4.91K Buy
+1,583
New +$7.46K ﹤0.01% 4184
2024
Q4 		– Sell
-346
Closed -$4.2K – 5798
2024
Q3 		$4.2K Buy
346
+205
+145% +$2.68K ﹤0.01% 4635
2024
Q2 		$1.67K Buy
141
+122
+642% +$1.93K ﹤0.01% 5112
2024
Q1 		$374 Sell
19
-295
-94% -$5.25K ﹤0.01% 5510
2023
Q4 		$5.66K Sell
314
-6
-2% -$92 ﹤0.01% 4819
2023
Q3 		$5.77K Buy
320
+238
+290% +$9.35K ﹤0.01% 4690
2023
Q2 		$5.18K Sell
82
-60
-42% -$3.27K ﹤0.01% 4852
2023
Q1 		$7K Sell
142
-164
-54% -$8.65K ﹤0.01% 4738
2022
Q4 		$9K Buy
306
+185
+153% +$7.67K ﹤0.01% 4199
2022
Q3 		$6K Buy
121
+17
+16% +$862 ﹤0.01% 5015
2022
Q2 		$4K Buy
104
+88
+550% +$4.04K ﹤0.01% 5206
2022
Q1 		$1K Buy
+16
New +$899 ﹤0.01% 5789
2021
Q4 		– Sell
-525
Closed -$47K – 6292
2021
Q3 		$47K Buy
525
+210
+67% +$22.5K ﹤0.01% 3015
2021
Q2 		$40K Buy
+315
New +$42.9K ﹤0.01% 3207

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Tower Research Capital (TRC)'s DMRA Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Damora Therapeutics, Inc. Ordinary Shares (DMRA) stake by 706% in Q1 2026, buying an estimated $31.9K and bringing the position to 1,418 shares worth $36.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3007.

Tower Research Capital (TRC) first reported a position in DMRA in Q2 2021 and has held it in 18 quarters since. The position peaked at $47K in Q3 2021. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

  • Tower Research Capital (TRC) held 1,418 shares of Damora Therapeutics, Inc. Ordinary Shares worth $36.7K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,242 Damora Therapeutics, Inc. Ordinary Shares shares in Q1 2026, an estimated $31.9K.
  • Damora Therapeutics, Inc. Ordinary Shares made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3007 holding.
  • Tower Research Capital (TRC) first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q2 2021 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s Damora Therapeutics, Inc. Ordinary Shares position peaked at $47K in Q3 2021.
  • 65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.